Clinical Trial

Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
To find the highest dose of NK cells that can be given by vein and intraperitoneally (given directly into the abdominal cavity) in combination with cetuximab to patients with colorectal cancer that has spread to the peritoneum.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-24
Trial Details
NCT Number NCT07411599
Lead Sponsor M.D. Anderson Cancer Center
Conditions Colorectal Cancer, Peritoneal Metastases, Carcinomatosis
Enrollment 28 participants
Start Date 2026-04-20
Primary Completion 2028-11-15 (estimated)
Study Completion 2030-11-15 (estimated)
Updated on ClinicalTrials.gov 2026-07-28